Human medicines European public assessment report EPAR Revlimid lenalidomide Multiple MyelomaLymphoma MantleCellMyelodysplastic Syndromes Date of authorisation 14062007 Revision 38 Status Authorised

Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 38, Status: Authorised

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 38, Status: Authorised"